Sanofi (NASDAQ:SNY) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. trimmed its stake in Sanofi (NASDAQ:SNY - Free Report) by 2.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 353,245 shares of the company's stock after selling 7,037 shares during the period. Rockefeller Capital Management L.P.'s holdings in Sanofi were worth $17,037,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of Sanofi by 26.3% in the 4th quarter. Sterling Capital Management LLC now owns 16,004 shares of the company's stock worth $772,000 after buying an additional 3,329 shares during the period. Argent Trust Co raised its holdings in shares of Sanofi by 4.0% in the fourth quarter. Argent Trust Co now owns 25,696 shares of the company's stock valued at $1,239,000 after acquiring an additional 996 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in Sanofi by 13.7% in the fourth quarter. Neuberger Berman Group LLC now owns 20,041 shares of the company's stock worth $967,000 after acquiring an additional 2,411 shares during the period. Scotia Capital Inc. grew its holdings in Sanofi by 7.1% during the 4th quarter. Scotia Capital Inc. now owns 8,677 shares of the company's stock worth $419,000 after acquiring an additional 572 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the period. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of SNY traded up $0.34 during trading hours on Friday, reaching $50.90. 2,856,361 shares of the company traded hands, compared to its average volume of 2,354,311. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average price of $54.73 and a 200-day moving average price of $52.19. Sanofi has a 12-month low of $45.79 and a 12-month high of $60.12. The stock has a market capitalization of $128.59 billion, a P/E ratio of 20.44, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's payout ratio is currently 59.04%.

Wall Street Analysts Forecast Growth

SNY has been the subject of several recent research reports. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. BNP Paribas initiated coverage on Sanofi in a report on Tuesday. They issued an "outperform" rating and a $65.00 price target on the stock. Finally, Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.